Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
Sangui Biotech International, Inc. focuses on developing and commercializing innovative biopharmaceutical products, particularly in the field of regenerative medicine. The company has a unique position in the market due to its proprietary technologies aimed at treating various diseases, including cancer and cardiovascular conditions, primarily targeting the North American and European markets.
Sangui Biotech generates revenue through the sale of its proprietary biopharmaceutical products and partnerships with larger pharmaceutical companies for research and development. The company's competitive advantage lies in its patented technologies and a strong pipeline of innovative therapies that address unmet medical needs.
FDA approval of new therapies, particularly for its lead product in regenerative medicine
Partnership announcements with larger pharmaceutical firms for co-development or licensing
Clinical trial results that demonstrate efficacy and safety of its products
Market expansion into Europe and Asia
Regulatory changes that could impact drug approval processes
Technological disruption from competitors developing more effective therapies
Emergence of generic alternatives to its proprietary products
Increased competition from larger pharmaceutical companies with more resources
Negative operating cash flow and free cash flow could limit operational flexibility
High reliance on future funding for R&D could strain liquidity
moderate - the demand for healthcare products can be somewhat insulated from economic downturns, but overall spending on healthcare can be affected by GDP growth.
High interest rates could increase the cost of capital for R&D and limit funding availability for clinical trials, negatively impacting growth prospects.
minimal - the company has a debt/equity ratio of -2.33, indicating a lack of reliance on debt financing.
growth - investors are likely attracted to the potential for high returns from innovative therapies and market expansion.
high - the stock has exhibited significant volatility, particularly with a recent 1-year return of -86.7%.